스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

amgen europe b.v. - filgrastim - soluciÓn inyectable en jeringa precargada - 48 millones u - filgrastim 96 millones u - filgrastim

에콰도르 - 스페인어 - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

amgen europe b.v. paises bajos - adalimumab 50 mg/ml cada jeringa prellenada (pfs) de 20 mg/0,4 ml contiene: adalimumab????????. 20 mg cada jeringa prellenada (pfs) o autoinyector prellenado de 40 mg/0,8 ml contiene: adalimumab???????? 40 mg - soluciÓn inyectable - cada jeringa prellenada (pfs) de 20 mg/0,4 ml contiene: adalimumab????????. 20 mg cada jeringa prellenada (pfs) o autoinyector prellenado de 40 mg/0,8 ml contiene: adalimumab???????? 40 mg

에콰도르 - 스페인어 - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

amgen europe b.v. [nl] netherlands - panitumumab 20mg/ml - concentrado para solucion para infusion - cada ml de concentrado contiene: panitumumab 20 mg

유럽 연합 - 스페인어 - EMA (European Medicines Agency)

amgen technology (ireland) uc - eculizumab - hemoglobinuria, paroxística - inmunosupresores - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidencia de beneficio clínico se ha demostrado en pacientes con hemólisis con síntoma clínico(s) indicativo de la alta actividad de la enfermedad, independientemente de los antecedentes de transfusión (véase la sección 5.

유럽 연합 - 스페인어 - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - inmunosupresores - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. el tratamiento de graves, activa y progresiva de la artritis reumatoide en adultos no tratados previamente con metotrexato. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita reduce la tasa de progresión del daño articular medido por rayos x y de mejora de la función física, cuando se administra en combinación con metotrexato. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita puede ser administrado como monoterapia en caso de intolerancia al metotrexato o cuando el tratamiento continuado con metotrexato no es la adecuada (para la eficacia en monoterapia véase la sección 5. adalimumab no ha sido estudiado en pacientes menores de 2 años. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita reduce la tasa de progresión de periféricos daño articular medido por rayos x en pacientes con poliarticular simétrica subtipos de la enfermedad (ver sección 5. 1) y mejora la función física. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 y 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

에콰도르 - 스페인어 - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

amgen europe b.v. paises bajos - trastuzumab 150 mg* *= excedente del 4% equivalente a 156 mg de trastuzumab, para dar como resultado un contenido recuperable de 150 mg/vial después de la reconstitución. - polvo para concentrado para solucion para perfusion - el vial contiene 150 mg de trastuzumab. tras la reconsitucion, 1 ml de concentrado contiene 21mg de trastuzumab

에콰도르 - 스페인어 - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

amgen europe b.v. paises bajos - cada ml de solucion reconstituida contiene 21mg/ml de trastuzumab. - polvo para concentrado para solucion para perfusion - trastuzumab 440mg* *el llenado objetivo de 440 mg se establece para dar como resultado un contenido recuperable de 420 mg/vial después de la reconstitución.

에콰도르 - 스페인어 - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

amgen inc. estados unidos - evolocumab ?? 140 mg/ml - soluciÓn inyectable - cada ml de solución contiene: evolocumab 140 mg

에콰도르 - 스페인어 - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

amgen inc. estados unidos - carfilzomib 60 mg/vial - polvo liofilizado para inyectable - cada vial contiene: carfilzomib 61.8 mg (a) (a) el volumen final después de la reconstitución con 29 ml de agua estéril para inyección asegura un volumen de extracción de 30 ml conteniendo 60 mg de carfilzomib

에콰도르 - 스페인어 - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

amgen manufacturing limited estados unidos - filgrastim 30 mu/0,5ml - solucion inyectable - cada jeringa precargada contiene: filgrastim 30 mu/0,5ml